Heron Therapeutics, Inc.

NASDAQ:HRTX

Biotechnology

Healthcare
$0.27 +3.74%

+$0.01 today

Market cap
$51.94M
Beta
1.57
P/E (TTM)
-2.5
EPS (TTM)
-$0.16
52W Low $0.38High $2.30

Volume 1.81M

Average 2.90M

HRTX Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Heron Therapeutics, Inc.NASDAQ: HRTX

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development growth accelerates

Q1 FY2026 research & development of $2.39M rose 4.7% year over year, ahead of the -12.7% change in trailing-twelve-month research & development. Sequentially, it fell 36.3% from the prior quarter. Over 3 fiscal years it compounded at -46.8% a year.

Context

  • Research & development amounted to 8.0% of revenue in FY2025, down 3.5 pp from a year earlier.
  • Research & development increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +4.7% holds above the trailing-twelve-month pace of -12.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.39M-36.3% QoQ
Last fiscal yearDec 2025
$12.43M-25.5% YoY
LTMMar 2026
$12.54M-12.7% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+4.7%——
1 year-25.5%——
3-year CAGR-46.8%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
12.43M USD
Year-over-year change
-25.5%
4-year CAGR
-44.5%

Research & Development vs competitors

How HRTX compares with its peers on the latest reported figures

  • HRTX's LTM Mar 2026 research & development of $12.54M is the 9th highest of the 10 companies compared; the peer median is $27.18M.
  • Its year-over-year change of -12.7% is the 7th highest of 9, against a peer median of +44.5%.
  • Research & development amounts to 8.3% of revenue for HRTX, versus a peer median of 114.8%.
HRTX Competitors Peer median
Research & Development for HRTX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CHRSCoherus Oncology, Inc.LTM Mar 2026$102.32M +17.6%-19.3%218.2%
IVVDInvivyd, Inc.LTM Mar 2026$58.4M -50.0%-40.2%104.5%
TARAProtara Therapeutics, Inc.LTM Mar 2026$46.96M +41.8%+36.4%—
OABIOmniAb, Inc.LTM Mar 2026$44.75M -15.8%-0.4%154.8%
EPRXEupraxia Pharmaceuticals Inc.LTM Mar 2026$27.18M +72.6%+29.4%—
SLSSELLAS Life Sciences Group, Inc.LTM Sep 2026$23.16M +47.2%-19.1%—
PLXProtalix BioTherapeutics, Inc.LTM Mar 2026$21.52M +58.7%-13.4%28.2%
MDWDMediWound Ltd.LTM Mar 2026$16.62M +61.4%+12.0%114.8%
HRTXHeron Therapeutics, Inc.LTM Mar 2026$12.54M -12.7%-46.8%8.3%
NTHINeonc Technologies Holdings, Inc.LTM Mar 2026$3.93M ———
Peer median (excluding HRTX) $27.18M+44.5%-6.9%114.8%

Competitors are the stored peer set for HRTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue86.35M107.67M127.04M144.29M154.9M
Cost of Revenue46.02M54.87M65.11M38.65M41.35M
Gross Profit40.33M52.8M61.94M105.64M113.56M
Gross Margin46.7%49.0%48.8%73.2%73.3%
Research & Development130.82M82.7M39.13M16.68M12.43M
Selling, General & Admin127.33M144.75M119.82M100.48M103.67M
Operating Expenses258.15M227.46M172.55M117.17M116.1M
Depreciation & Amortization3.02M2.89M2.9M2.49M2.31M
EBITDA(215.25M)(176.66M)(103.79M)(5.06M)(17.88M)
EBITDA Margin-249.3%-164.1%-81.7%-3.5%-11.5%
Operating Income(217.83M)(174.66M)(110.62M)(11.53M)(2.54M)
Operating Margin-252.3%-162.2%-87.1%-8.0%-1.6%
Interest Income433K1.64M3.36M3.55M0
Interest Expense2.41M2.47M3.87M6.03M0
Other Income / Expenses(2.86M)(7.37M)56K(2.05M)(17.66M)
Income Before Tax(220.68M)(182.02M)(110.56M)(13.58M)(20.2M)
Pre-Tax Margin-255.6%-169.1%-87.0%-9.4%-13.0%
Income Tax Expense00000
Net Income(220.68M)(182.02M)(110.56M)(13.58M)(20.2M)
Net Margin-255.6%-169.1%-87.0%-9.4%-13.0%
EPS (Basic)(2.24)(1.67)(0.80)(0.09)(0.12)
EPS (Diluted)(2.24)(1.67)(0.80)(0.09)(0.12)
Weighted Avg Shares98.47M109M138.14M152.45M166.71M
Weighted Avg Shares (Diluted)98.47M109M138.14M152.45M166.71M

Heron Therapeutics, Inc.

NASDAQ:HRTX

Intrinsic Alpha fair value

Locked

Current Price

$0.27

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.